To review the pathophysiology of hypertension and complications in patients with diabetes mellitus, specifically focusing on diabetic nephropathy; to evaluate the current clinical literature regarding the appropriate management of hypertension in this patient group; and to offer treatment recommendati
DATA SOURCES:
A MEDLINE search of applicable English-language clinical studies, abstracts, and review articles pertaining to hypertension, diabetes, and diabetic nephropathy.
STUDY SELECTION:
Relevant studies on humans, examining hypertension, diabetes, and diabetic nephropathy, and the effects of drug therapy on these interrelated disease states.
DATA SYNTHESIS:
Pathophysiology of hypertension in the patient with diabetes mellitus and the pathophysiology of diabetic nephropathy are discussed. Studies evaluating the therapeutic effect of certain antihypertensive agents, their effect on glucose control and insulin sensitivity, and the progression of diabetic nephropathy are reviewed. Recommendations on the treatment of the patient with diabetes and hypertension are given.
CONCLUSIONS:
The treatment of the patient with diabetes mellitus and hypertension remains complex. Interventions in this patient population should not only decrease blood pressure, but also reduce the risk of both vascular and nonvascular complications. Data support the theory that by controlling a patient's hypertension, the incidence of albuminuria and the progression of diabetic nephropathy are slowed. Additionally, data are available to support the use of pharmacologic interventions in nonhypertensive patients with diabetes and proteinuria. Drug therapies that have produced reductions in proteinuria in this patient population include angiotension-converting enzyme inhibitors and nondihydropyridine calcium-channel antagonists. Additional information is needed to better differentiate the individual agents within each of the antihypertensive drug classes regarding their individual effects on the patient with diabetes and hypertension, specifically effects on diabetic nephropathy and its progression to endstage renal disease.
Get full access to this article
View all access options for this article.
References
1.
HoustonMC. Treatment of hypertension in diabetes mellitus. Am Heart J1989; 118: 819–29.
2.
American Diabetes Association Consensus Statement. Treatment of hypertension in diabetes. Diabetes Care1993; 16: 1394–401.
Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressures. Arch Intern Med1993; 153: 154–83.
5.
TuckM. Management of hypertension in the patient with diabetes mellitus: focus on the use of angiotensin-converting enzyme inhibitors. Am J Hypertens1988; 1 (suppl): 384–8S.
6.
ValentinoVAWilsonMDWeartWBakrisGL. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med1991; 151: 2367–72.
7.
KrolewskiASWarramJHChristliebARBusickEJKahnCR. The changing natural history of nephropathy in type I diabetes. Am J Med1985; 78: 785–94.
8.
ChristliebARKaldanyAD'EliaJAWilliamsGH. Aldosterone responsiveness in patients with diabetes mellitus. Diabetes1978; 27: 732–7.
9.
BakrisGL. Pathogenesis of hypertension in diabetics. Diabetes Rev (in press).
10.
ModanMHalkinHAlmogSLuskyAEsckolAShefiM. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest1985; 75: 809–17.
11.
ChristliebARKrolewskiASWarramJHSoeldnerJS. Is insulin the link between hypertension and obesity?Hypertension1985; 7 (6 pt 2): 1154–7.
12.
YoungJBLandsbergL. Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. J Chron Dis1982; 35: 879–86.
13.
GerberLMScmuklerCAldermanMH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and non-white subjects. Arch Intern Med1992; 152: 373–7.
14.
National High Blood Pressure Education Program (NHBPEP) Working Group. The NHBPEP Working Group report on hypertension and chronic renal failure. Arch Intern Med1991; 151: 1280–7.
15.
ParvingHHSmidtUMHommelEMathiesonERRossingPNeilsonF. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis1993; 22: 188–95.
16.
MogensenCE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med1984; 310: 356–60.
17.
MattockMBMarrishNJVibertiGKeenHFitzgeraldAPJacksonG. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes1992; 41: 736–41.
18.
AbbottKCSaudergLBakrisGL. Microalbuminuria in type II diabetes: implications for renal survival. Arch Intern Med1993; 154: 146–52.
19.
National High Blood Pressure Education Program (NHBPEP) Working Group. The NHBPEP working group report on hypertension in diabetes. Hypertension1994; 23: 145–58.
20.
KleinRKleinBEKMossSEDavisMEDeMetsD. The Wisconsin epidemiology study of diabetic retinopathy II: prevalence and risk of diabetic retinopathy when eye at diagnosis is less than 30 years. Arch Ophthalmol1984; 102: 520–9.
21.
MogensenCEChristensenCKVittinghusE. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes1983; 32 (suppl 2): 64–78.
22.
SelbyJVFitzsimmonsSCNewmanJMKatzPPSepeSShowstackJ. The natural history and epidemiology of diabetic nephropathy. JAMA1990; 263: 1954–60.
23.
HoelscherDDWeirMRBakrisGL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharm1995; 35: 73–80.
24.
BrancatiFLWhittleJCWheltonPKSeidlerAJKlagMJ. The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA1992; 268: 3079–84.
25.
CowieCCPortFKWolfeRASavagePJMollPPHawthorneVM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med1989; 321: 1074–9.
26.
ChristliebAR. Treatment selection considerations for the hypertensive diabetic patient. Arch Intern Med1990;(150c-6):1167–74.
27.
ChristensenJSGammelgaardJTronierBSvenderPAParvingHH. Kidney function and size in diabetics before and during initial insulin treatment. Kidney Int1982; 21: 683–8.
28.
RossingPHommelESmidtUMParvingHH. Reduction in albuminuria predicts diminished pregression in diabetic nephropathy. Kidney Int1994; 45 (suppl 45): S145–9.
29.
RavidMSavinHJutrinIBentalTKatzBLishnerM. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med1993; 118: 577–81.
30.
BakrisGLBarnhillBWSadlerR. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int1992; 41: 912–9.
31.
LewisEJHunsickerLGBainRPRhodeRD. The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med1993; 323: 1456–62.
32.
BakrisGL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med1993; 118: 643–4.
BakrisGLWilliamsB. Angiotensin-wconverting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?J Hypertens1995; 13 (suppl): S95–102.
35.
GansevoortRTde ZeeuwDde JongPE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?Kidney Int1994; 45: 861–7.
36.
AndersonSRennkeHGZatzR. Glomerular adaptations with normal aging and with long-term converting inhibition in rats. Am J Physiol1994; 267 (suppl): F35–43.
37.
MyersBD. Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens1990; 8 (suppl): S41–6.
38.
MakiDDMaJZLouisTAKaisiskeBL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med1995; 155: 1073–80.
39.
BakrisGL. Hypertension in diabetic patients: an overview of interventional studies to preserve renal function. Am J Hypertens1993; 6 (suppl): 140–7s.
40.
HartmannALundKHoldaasHFauchaldPReisaeterABergKJ. Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerular nephritic patients. Am Soc Nephrol1994; 5: 1385–90.
41.
GaberLWaltonCBrownSBakrisG. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int1994; 46: 161–9.
42.
SlataperRVicknairNSadlerRBakrisGL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med1993; 153: 973–80.
43.
National High Blood Pressure Educational Program (NHBPEP) Working Group. The NHBPEP Working Group report on primary prevention of hypertension. Arch Intern Med1993; 153: 186–208.
44.
HeegJEde JongPEVander HemGKde ZeeuwD. Efficacy and variability of the antiproteinemic effect of ACE inhibition by lisinopril. Kidney Int1989; 36: 272–9.
45.
The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993; 329: 977–86.
46.
American Diabetes Association, National Kidney Foundation. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care1994; 17: 1357–61.
47.
BerneCPollareTLithellH. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE-inhibitors. Diabetes Care1991; 14 (suppl 4): 39–47.
48.
TorloneERambottiAMPerrielloGBottaGSanteusanioFBrunettiP. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type II (non-insulin dependent) diabetes mellitus and arterial hypertension. Diabetalogia1991; 34: 119–25.
49.
PrinceMJStuartCAPadiaMBandiZHollandOB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med1988; 148: 2363–8.
50.
TakasakiIShionoiriHHirotoSYasudaGGotohEUmemuraS. Long-term captopril therapy with no effect on glucose metabolism in patients with essential hypertension. Am J Hypertens1988; 1 (suppl): S217–20.
51.
PollareTLithellHBerneC. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med1989; 321: 868–73.
52.
VibertiGMogensenCEGroopLCPaulsJF. European Microalbuminuria Captopril Study: effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA1994; 271: 275–9.
53.
BabaTIshizakiT. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy: effects of antihypertensive drugs on kidney function and insulin sensitivity. Drugs1992; 43: 464–89.
54.
ChellingsworthMCKendallMJWrightADSinghBMPasiJ. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with NIDDM. J Hum Hypertens1989; 3: 35–9.
55.
CaldwellBV. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers. Clin Ther1993; 15: 618–36.
56.
CapewellSCollierAMatthewsDHajduckaCCollierRClarkeBF. A trial of the calcium antagonist felodipine in hypertensive type-2 diabetic patients. Diabetic Med1989; 6: 809–12.
57.
VeenstraJvan der HulstJPWildenborgIHNjooSFVerdegallWPSilberbuschJ. Effect of antihypertensive drugs on insulin absorption. Diabetes Care1991; 14: 1089–92.
58.
BakrisGL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med1990; 122: 701–2.
59.
MimranAInsuaARibsteinJMonnierLBringerJMirouseJ. Contrasting effects captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens1988; 6: 919–23.
60.
DiamondJRCheungJYFangLS. Nifedipine-induced renal dysfunction. Am J Med1984; 77: 905–9.
61.
DemarieBKBakrisGL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med1990; 113: 987–8.
62.
BrownSAWaltonCLCrawfordPBakrisGL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int1993; 43: 1210–8.
63.
KaplanNM. Clinical hypertension. 6th ed. Baltimore, MD: Williams and Wilkins Co., 1994: 260–2.
64.
HupponenRLehtonenAVahataloM. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol1992; 43: 365–8.
65.
LithellHOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care1991; 14: 203–9.
66.
PollareTLithellHSelinusIBerneC. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia1988; 31: 415–20.
67.
LehtonenA. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J1991; 121 (4 part 2): 1307–11.
68.
PrisantLMCarrAA. Antihypertensive drug therapy and insulin resistance. Am J Hypertens1992; 5: 775–7.
69.
HarrowerADBMcFarlaneG. Antihypertensive therapy in diabetic patients: the use of indapamide. Am J Med1988; 84 (suppl 1B): 89–91.
70.
BrassEP. Effects of antihypertensive drugs on endocrine function. Drugs1984; 27: 447–58.
71.
GambardellaSFrontiniSFeliciMGSpalloneVGarguiloPMornanoS. Efficacy of antihypertensive treatment with indapamide in patients with non-insulin-dependent diabetes and persistent microalbuminuria. Am J Cardiol1990; 65 (suppl): 46–50H.
72.
GroopLTottermanKJHarnoKGordinA. Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand1982; 211: 7–12.
73.
PollareTLithellHSelinusIBerneC. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J1989; 298: 1152–7.
74.
MillsGAHornJR. β-blockers and glucose control. Drug Intell Clin Pharm1985; 19: 246–51.
75.
BjorkSMulecHJohnsonSANybergGAurellM. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ1990; 300: 904–7.
76.
KasiskeBLKalilRSNMaJZLiaoMKeaneWF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med1993; 118: 129–38.
77.
StornelloMValvoEVScapellatoL. Angiotensin converting enzyme inhibitor in normotensive type II diabetics with persistent mild proteinuria. J Hypertens1988; 7 (suppl): S464–6.
78.
RudbergSAperiaAFreyschussUPerssonB. Enalapril reduces microalbuminuria in young normotensive type I (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia1990; 33: 470–6.
79.
MathiesenERHommelEGieseJParvingHH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ1991; 303: 81–7.
80.
CookJDanemanDSpinoMSochettEPerimanKBalfeJW. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr1990; 117: 39–45.
81.
KnowlerWCKunzelmanCL. Population comparisons of the frequency of diabetic nephropathy. In: MogensenCE, eds. The kidney and hypertension in diabetes mellitus. Boston: Martinus Nijhoff, 1988: 25–32.
